Zhaoxiang Ren1, Pengju Yan1, Liushuai Zhu1, Huicui Yang1, Yafei Zhao1, Brian P Kirby2, John L Waddington1,3, Xuechu Zhen4,5. 1. Jiangsu Key laboratory for Translational Research and Therapy for Neuropsychiatric disorders, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu Province, 215123, China. 2. School of Pharmacy, Royal College of Surgeons in Ireland, Dublin 2, Ireland. 3. Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin 2, Ireland. 4. Jiangsu Key laboratory for Translational Research and Therapy for Neuropsychiatric disorders, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu Province, 215123, China. zhenxuechu@suda.edu.cn. 5. The Collaborative Innovation Center for Brain Science, Soochow University, Suzhou, Jiangsu Province, 215123, China. zhenxuechu@suda.edu.cn.
Abstract
RATIONALE: Major depressive disorder (MDD) is a highly prevalent illness that affects large populations across the world, and increasing evidence suggests that neuroinflammation and levels of brain-derived neurotrophic factor (BDNF) are closely related to depression. Dihydromyricetin (DHM) is a kind of flavonoid natural product that has been reported to display multiple pharmacological effects, including anti-inflammatory and anti-oxidative properties, and these may contribute to ameliorate MDD. OBJECTIVE: This study investigated the effect of DHM on depression-related phenotypes in various experimental animal models. METHODS: The antidepressant-like effect of DHM was validated via depression-related behavioral tests in naïve male C57BL/6 mice, as well as in the acute lipopolysaccharide-induced mouse model of depression. The chronic unpredicted mild stress (CUMS) mouse model of depression was also used to assess the rapid antidepressant-like effect of DHM by tail suspension test (TST), forced swimming test (FST), locomotor activity, and sucrose preference test (SPT). The expression of BDNF and inflammatory factors were determined through Western blotting and enzyme-linked immunosorbent assay, respectively. RESULTS: DHM reduced immobility time in the TST and FST both in mice and the acute LPS-induced mouse model of depression. Seven days of DHM treatment ameliorated depression-related behaviors induced by CUMS, whereas similar treatment with the typical antidepressant venlafaxine did not. DHM activated the ERK1/2-CREB pathway and increased glycogen synthase kinase-3 beta (GSK-3β) phosphorylation at ser-9, with upregulation of BDNF expression, in both hippocampal tissues and cultured hippocampal cells. CONCLUSION: The present data indicate that DHM exerts a more rapid antidepressant-like effect than does a typical antidepressant, in association with enhancement of BDNF expression and inhibition of neuroinflammation.
RATIONALE: Major depressive disorder (MDD) is a highly prevalent illness that affects large populations across the world, and increasing evidence suggests that neuroinflammation and levels of brain-derived neurotrophic factor (BDNF) are closely related to depression. Dihydromyricetin (DHM) is a kind of flavonoid natural product that has been reported to display multiple pharmacological effects, including anti-inflammatory and anti-oxidative properties, and these may contribute to ameliorate MDD. OBJECTIVE: This study investigated the effect of DHM on depression-related phenotypes in various experimental animal models. METHODS: The antidepressant-like effect of DHM was validated via depression-related behavioral tests in naïve male C57BL/6 mice, as well as in the acute lipopolysaccharide-induced mouse model of depression. The chronic unpredicted mild stress (CUMS) mouse model of depression was also used to assess the rapid antidepressant-like effect of DHM by tail suspension test (TST), forced swimming test (FST), locomotor activity, and sucrose preference test (SPT). The expression of BDNF and inflammatory factors were determined through Western blotting and enzyme-linked immunosorbent assay, respectively. RESULTS:DHM reduced immobility time in the TST and FST both in mice and the acute LPS-induced mouse model of depression. Seven days of DHM treatment ameliorated depression-related behaviors induced by CUMS, whereas similar treatment with the typical antidepressant venlafaxine did not. DHM activated the ERK1/2-CREB pathway and increased glycogen synthase kinase-3 beta (GSK-3β) phosphorylation at ser-9, with upregulation of BDNF expression, in both hippocampal tissues and cultured hippocampal cells. CONCLUSION: The present data indicate that DHM exerts a more rapid antidepressant-like effect than does a typical antidepressant, in association with enhancement of BDNF expression and inhibition of neuroinflammation.
Authors: Kuresh A Youdim; Michael S Dobbie; Gunter Kuhnle; Anna R Proteggente; N Joan Abbott; Catherine Rice-Evans Journal: J Neurochem Date: 2003-04 Impact factor: 5.372
Authors: Elena Dale; Alan L Pehrson; Theepica Jeyarajah; Yan Li; Steven C Leiser; Gennady Smagin; Christina K Olsen; Connie Sanchez Journal: CNS Spectr Date: 2015-09-08 Impact factor: 3.790
Authors: José Rogério Souza-Monteiro; Gabriela P F Arrifano; Ana Isabelle D G Queiroz; Bruna S F Mello; Charllyany S Custódio; Danielle S Macêdo; Moisés Hamoy; Ricardo S O Paraense; Leonardo O Bittencourt; Rafael R Lima; Rommel R Burbano; Hervé Rogez; Cristiane F Maia; Barbarella M Macchi; José Luiz M do Nascimento; Maria Elena Crespo-López Journal: Oxid Med Cell Longev Date: 2019-07-24 Impact factor: 6.543